Home
Interesting shortcuts
News Dashboard
Projects
Projects
Results, demos etc.
Results, demos etc.
Structured Wiki
Search
FoF and Made in Europe Partnership
Demonstrators, pilots, prototypes
Exploitable result(s)
Significant innovations and lessons learned, training aspects
Report - Video - Presentation - Publication....?
Project clusters
Company perspectives
Manufacturing future products
Manufacturing performance characteristics
Technologies and enablers
ICT performance characteristics
Standards and standardisation
Contribution of R&I projects to standardisation
Regulatory and policy aspects
Standards - other classifications
Business model aspects
Pathways
MiE SRIA R&I Priorities
Public Consultation - MiE 25-27 Priorities (input is publicly available)
MiE KPIs
Relevant open calls
EU-Programme-Call
NACE code
Pathways
Pathways
Project ideas
Project ideas
People & organisations
People
Organisations
portal@effra.eu
Visit the EFFRA website
Login
Projects
UPTIME
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
UPTIME
mapped on
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-01 Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
IMI2-2017-13-02 Genome-Environment Interactions in Inflammatory Skin Disease
IMI2-2017-13-03 The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
IMI2-2017-13-04 Mitochondrial Dysfunction in Neurodegeneration
IMI2-2017-13-05 Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative
IMI2-2017-13-06 A sustainable European induced pluripotent stem cell platform
IMI2-2017-13-07 Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
IMI2-2017-13-08 Human Tumour Microenvironment Immunoprofiling
IMI2-2017-13-09 ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
IMI2-2017-13-10 Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
IMI2-2017-13-11 Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
IMI2-2017-13-14 Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
IMI2-2017-13-15 Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases